Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tema Obesity & Cardiometabolic ETF
(NQ:
HRTS
)
32.67
-0.23 (-0.70%)
Official Closing Price
Updated: 4:15 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tema Obesity & Cardiometabolic ETF
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test
April 17, 2024
The results also pressured ResMed, a maker of CPAPs. CPAPs are the common treatment for sleep apnea.
Via
Investor's Business Daily
Healthcare ETFs For The Weight-Loss Drug Boom And Beyond
April 08, 2024
Two dominant investing themes over the past year have been AI and weight-loss drugs.
Via
Talk Markets
Topics
Artificial Intelligence
ETFs
Exposures
Artificial Intelligence
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
February 23, 2024
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.
Via
Investor's Business Daily
Ozempic, Weygovy – Obesity And Heart Health Constitute A Major Market That Is Only Growing
January 29, 2024
David Song, PM of the Cardiovascular and Metabolic ETF (NASDAQ: HRTS) for Tema ETFs, was recently interviewed by Benzinga.
Via
Benzinga
Topics
ETFs
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
December 04, 2023
Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic
Via
Benzinga
EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads
December 01, 2023
Tema ETFs is redefining thematic investing, focusing on long-term structural trends & precision in security selection rather than chasing short-term fads.
Via
Benzinga
Topics
ETFs
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.